---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-066327"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:44:50.376395+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aldeyra achieves primary endpoint in Phase 3 dry eye trial of reproxalap; NDA resubmission planned 2024

## Summary
- Primary endpoint of ocular discomfort met (p=0.004) vs vehicle in 132-patient Phase 3 dry eye chamber trial.
- NDA resubmission for reproxalap anticipated in 2024; FDA review period expected ~6 months.
- Reproxalap studied in over 2,500 patients; no safety signals; mild transient instillation site discomfort most common AE.
- Option agreement with AbbVie includes $100M upfront if exercised, plus up to $300M milestones and profit/loss share.

## SEC filing metadata
- accession: 0001213900-24-066327
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000121390024066327/0001213900-24-066327-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000121390024066327/ea0210840-8k_aldeyra.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-066327
- JSON: https://secwatch.observer/filing/0001213900-24-066327.json
- Plain text: https://secwatch.observer/filing/0001213900-24-066327.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.